Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Has Consensus Price Target of $44.00 According to Analysts

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have received an average recommendation of “Buy” from the twelve research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $46.50.

Several research firms recently weighed in on DMRA. HC Wainwright reiterated a “buy” rating and issued a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Guggenheim upped their price objective on shares of Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Friday. TD Cowen raised shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. Wedbush lifted their target price on shares of Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, July 30th. Finally, Jefferies Financial Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They set a “buy” rating and a $50.00 price target on the stock.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of DMRA stock opened at $20.66 on Friday. The firm has a market cap of $1.28 billion, a P/E ratio of -6.13 and a beta of 1.46. Damora Therapeutics, Inc. Common Stock has a fifty-two week low of $3.50 and a fifty-two week high of $38.33. The business’s 50 day moving average price is $28.43 and its 200-day moving average price is $26.34.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.06. As a group, equities analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current year.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Several large investors have recently bought and sold shares of the company. Braidwell LP purchased a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $42,146,000. Seven Fleet Capital Management LP purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at approximately $7,398,000. Squarepoint Ops LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the second quarter valued at approximately $303,000. Finally, Arizona State Retirement System bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the second quarter valued at approximately $260,000. 14.20% of the stock is owned by institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.